Cargando…
Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
T cell engaging bispecific antibody (TCB) is an effective immunotherapy for cancer treatment. Through co-targeting CD3 and tumor-associated antigen (TAA), TCB can redirect CD3(+) T cells to eliminate tumor cells regardless of the specificity of T cell receptor. Tissue factor (TF) is a TAA that invol...
Autores principales: | Pan, Zhidi, Chen, Jie, Xiao, Xiaodong, Xie, Yueqing, Jiang, Hua, Zhang, Baohong, Lu, Huili, Yuan, Yunsheng, Han, Lei, Zhou, Yuexian, Zong, Huifang, Wang, Lei, Sun, Rui, Zhu, Jianwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279644/ https://www.ncbi.nlm.nih.gov/pubmed/35847491 http://dx.doi.org/10.1016/j.apsb.2021.10.028 |
Ejemplares similares
-
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
por: Zhou, Yuexian, et al.
Publicado: (2020) -
A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer
por: Chen, Jie, et al.
Publicado: (2021) -
A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
por: Sun, Rui, et al.
Publicado: (2021) -
Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
por: Chen, Jie, et al.
Publicado: (2023) -
Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system
por: Han, Lei, et al.
Publicado: (2017)